How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,615 results for

HIV Exposure

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

15541. Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations

Outcome Measures : Frequency of unprotected sexual acts with nonspousal partners [ Time Frame: Measured at baseline and Years 1 and 2 ] Overall observed incidence of sexually transmitted diseases (STDs) (e.g., chlamydia, gonorrhea, syphilis, trichomonas, HIV, or herpes simplex virus-2), as detected by biological specimens [ Time Frame: Measured at baseline and Years 1 and 2 ] Secondary Outcome Measures : Increased exposure to HIV prevention messages, more STD treatment seeking, lower stigma regarding (...) Community Prevention International Global Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Immunologic Deficiency Syndromes Immune System Diseases Infection Genital Diseases, Male Genital Diseases, Female

2008 Clinical Trials

15542. Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

: Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 [ Time Frame: Baseline (Day 1) and Day 11 ] Change from Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) was calculated as the Day 11 value minus the Baseline value. Blood samples for the measurement of HIV-1 RNA levels were obtained throughout the treatment period (Day 1 to Day 11). Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) Extrapolated (...) -ranging study phase IIa integrase inhibitor HIV-1 infection Additional relevant MeSH terms: Layout table for MeSH terms Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Dolutegravir Integrase Inhibitors HIV Integrase Inhibitors Enzyme Inhibitors Molecular Mechanisms

2008 Clinical Trials

15543. HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers

Posted : July 2, 2017 Sponsor: National Cancer Institute (NCI) Information provided by: National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: Background: The incidence of lung cancer is quite high among people with the human immunodeficiency (HIV) virus. Frequent smoking may explain that cancer increase, given that 50% to 70% of HIV-infected people are current smokers. Recent research suggests that other factors may be involved as well. Smoking habits (...) current tobacco smokers and 100 participants who report no recent cigarette use. Condition or disease HIV Infections AIDS Lung Cancer Tobacco Addiction Drug Addiction Detailed Description: Lung cancer incidence is substantially elevated among people infected with human immunodeficiency virus (HIV). Although frequent smoking may partly explain this increase, recent work suggests other factors may also be involved. To better characterize smoking habits and lung cancer risk in HIV-infected people

2007 Clinical Trials

15544. Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies

relapsers Additional relevant MeSH terms: Layout table for MeSH terms Hepatitis Hepatitis A Hepatitis C HIV Infections Hepatitis, Chronic Hepatitis C, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections Lentivirus Infections Retroviridae Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases (...) Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2007 Clinical Trials

15545. HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding

virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) with daily valacyclovir will reduce HIV-1 levels in plasma, genital, and breast milk and will decrease the risk of mother-to-child HIV-1 transmission (MTCT). Condition or disease Intervention/treatment Phase HIV Infections Herpes Simplex Drug: valacyclovir Drug: placebo Phase 2 Detailed Description: Each year over 500,000 children become HIV-1-infected in sub-Saharan Africa after exposure to maternal virus in blood, genital secretions (...) 17, 2007 Results First Posted: April 18, 2012 Last Update Posted: December 19, 2018 Last Verified: November 2018 Keywords provided by Carey Farquhar, University of Washington: Disease Transmission, Vertical valacyclovir Randomized Controlled Trials HIV herpes Herpesvirus 2, Human HIV Seronegativity Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Herpes Simplex Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases

2007 Clinical Trials

15546. Phase 1 Safety Study of Two Experimental HIV Vaccines

are made using an adenovirus (virus that normally causes respiratory infections and colds) that has been modified to contain DNA that codes for HIV proteins. The vaccines cannot cause HIV or adenoviral infections. Healthy normal volunteers between 18 and 50 years of age may be eligible for this 2-part study. Part 1 includes 15 people. Part 2 includes 20 people. Part 1 participants receive only the rAd35-EnvA vaccine. The first five people enrolled receive the lowest study dose of the vaccine (...) infection risks, amenable to risk reduction counseling, committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit and assessed by the clinic staff as being at low risk of HIV infection on the basis of behaviors in the 12 months prior to enrollment as follows: Sexually abstinent OR Had two or fewer mutually monogamous relationships with partners believed to be HIV-uninfected and who did not use injection drugs, crack cocaine

2007 Clinical Trials

15547. ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

Study ID Numbers: ML19355 First Posted: April 17, 2007 Last Update Posted: August 24, 2016 Last Verified: August 2016 Keywords provided by Hoffmann-La Roche: Treatment Experienced Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Anti-Retroviral Agents Enfuvirtide Antiviral (...) ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression. ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x

2007 Clinical Trials

15548. PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

developed a new ligand, N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine [11C]PBR28, which showed much greater specific signal than [11C]PK11195 in non-human primates. ln the present protocol we plan to perform a kinetic brain imaging study with [11C]PBR28 in HlV-seronegative controls, HIV-seropositive, non-impaired patients, and HlV-seropositive patients with minor cognitive motor disorder(MCMD). Each subject will recieve a brain-dedicated PET scan with 20 mCi[(11)C]PBR28. Study Design Go (...) Health (NIMH) ): HIV-Dementia Brain PET PBR28 MCMD HIV Positive HIV Dementia AIDS Related Dementia Minor Cognitive Motor Disorder Healthy Volunteer HV Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Dementia Alzheimer Disease Brain Diseases HIV Seropositivity AIDS Dementia Complex Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System

2007 Clinical Trials

15549. Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m^2 every 8 hours; pediatric participants > 12 years of age: 300 mg twice daily). Outcome Measures Go to Primary Outcome Measures : Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 [ Time Frame: 48 weeks ] This is the percentage of participants with HIV-1 RNA < 400 copies/mL after 48 weeks of exposure to randomized study drug. Secondary Outcome Measures : Virologic Success at 48 Weeks (HIV-1 RNA (...) Cutoff at 400 Copies/mL, Snapshot) [ Time Frame: 48 weeks ] This is the percentage of participants with virologic success after 48 weeks of exposure to randomized study drug. The percentage of participants achieving HIV-1 RNA < 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Virologic Success

2007 Clinical Trials

15550. Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

will be randomized to one of the following in a 1:2 ratio: ARM A: FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ritonavir 100 mg QD ARM B: FTC 200 mg/TDF 300 mg QD + darunavir 800mg/ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID The three primary objectives are: To assess whether a multi-class regimen could completely suppress virus replication in HIV infected individuals based on: Plasma HIV-1 RNA levels at 48 weeks Ultrasensitive < 50 copy assay 5 copy assay 1 copy assay Cell associated HIV (...) : No Criteria Inclusion Criteria: Acute HIV-1 infection defined as: Negative ELISA/Western Blot or indeterminate Western Blot in the presence of HIV-1 RNA > 5,000 copies/ml. Positive HIV-1 serology with a detuned ELISA O.D. value below 0.5. A documented negative serology within 180 days of screening and a positive HIV-1 serology at screening Antiretroviral (ARV) drug-naïve (defined as ≤ 7 days of ARV treatment at any time prior to entry*). The only exceptions are: Use of antivirals as part of post-exposure

2007 Clinical Trials

15551. Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

the pharmacokinetics and long term plasma exposure of the following antiretrovirals: atazanavir when combined to ritonavir and the tenofovir/emtricitabine fixed-dose combination. All drugs will be delivered in MEMS electronic device to monitor dosing history. Condition or disease Intervention/treatment Phase HIV Infections Drug: Atazanavir Drug: Ritonavir Drug: Tenofovir/emtricitabine Phase 2 Detailed Description: The trial is a phase II, open label, non-randomized, prospective multicenter trial to assess (...) Official Title: Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 Cophar 3 Study Start Date : January 2008 Actual Primary Completion Date : November 2008 Actual Study Completion Date : November 2008 Resource links provided by the National Library of Medicine related topics: available for: Arms

2007 Clinical Trials

15552. Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection

Immune System Diseases Hepadnaviridae Infections DNA Virus Infections Hepatitis, Viral, Human Hepatitis Liver Diseases Digestive System Diseases Parasitic Diseases Tenofovir Emtricitabine Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents (...) have only recently commenced. No such trials have been undertaken in the HIV/HBV co-infected population. Condition or disease Intervention/treatment Phase Hepatitis B Virus HIV Infections Drug: Emtricitabine Phase 2 Detailed Description: The primary study objective is to compare HBV DNA suppression to levels below the limit of detection (<400 copies/ml) by week 48 in each treatment group. Virological and clinical anti-HBV efficacy of tenofovir and emtricitabine in antiretroviral naive patients

2007 Clinical Trials

15553. Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients

: The purpose of this study is to determine if CP-675,206, a monoclonal antibody to CTLA4, is safe and well-tolerated, reduces viral load, and improves immune function in patients infected with HIV. Condition or disease Intervention/treatment Phase Human Immunodeficiency Virus Drug: CP-675,206 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 0 participants Allocation: Randomized Intervention Model: Single Group Assignment Masking (...) : Single Primary Purpose: Treatment Official Title: A Phase 2 Study To Evaluate The Safety, Tolerability, Virologic And Immunologic Effect Of Single-Dose CP-675,206 In Patients Infected With Human Immunodeficiency Virus Study Start Date : July 2007 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Outcome Measures Go to Primary Outcome Measures : Maximum reduction in HIV plasma RNA between Baseline and Week 12 Maximum increase in CD4+ cell count

2007 Clinical Trials

15554. Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Vitamins Vitamin D Ergocalciferols Cholecalciferol Tenofovir Micronutrients Nutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents Calcium-Regulating Hormones and Agents Antiviral Agents Anti-Infective Agents Reverse (...) Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Vitamin D

2007 Clinical Trials

15555. The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants

(AIDS) at a very young age. Exposure to other infectious diseases may influence this early progression to AIDS. BCG is a live tuberculosis vaccine made from cow tuberculosis. It is routinely given at birth to most babies, also to babies born to HIV-positive mothers. BCG can cause disease (BCGosis) in HIV-infected babies. More importantly, BCG may also trigger immune responses in the body that lead to the spread of the HIV virus and early progression to AIDS. Objective(s) and Hypothesis (...) : The researchers will investigate whether BCG causes progression of HIV by doing a clinical trial: babies born to HIV-positive mothers will be randomly allocated to get the BCG vaccine at birth or at 14 weeks of age. In these 2 groups of babies, the researchers will compare: The percentage of babies who progress to HIV disease Blood markers of HIV disease (the amount of virus and protective white blood cells in the body) The body's immune response to BCG vaccine and other childhood vaccines The percentage

2006 Clinical Trials

15556. Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children

Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00330304 Recruitment Status : Unknown Verified September 2010 by University of Cape Town. Recruitment status was: Active, not recruiting First Posted : May 26, 2006 Last Update

2006 Clinical Trials

15557. Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

provided by (Responsible Party): Bristol-Myers Squibb Study Details Study Description Go to Brief Summary: To determine what dosing regimen of atazanavir (ATV) / ritonavir (RTV) produces adequate drug exposure during pregnancy compared to drug exposure in historical data in human immunodeficiency virus (HIV) infected participants. Condition or disease Intervention/treatment Phase HIV Infection Drug: Atazanavir + Ritonavir + Combivir Phase 1 Study Design Go to Layout table for study information Study (...) or on ATV/RTV combined with ZDV/3TC Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Atazanavir Sulfate Lamivudine, zidovudine drug combination HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV

2006 Clinical Trials

15558. Addressing Young Men's Substance Use and HIV Risk

Addressing Young Men's Substance Use and HIV Risk Addressing Young Men's Substance Use and HIV Risk - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Addressing Young Men's Substance Use and HIV Risk (Get (...) the development of the intervention. The effects of the intervention will be assessed through annual interviews with young Black and White MSM in Philadelphia where the intervention will be implemented and in Baltimore, our comparison community. Condition or disease Intervention/treatment Phase HIV Behavioral: community-level intervention for young MSM Not Applicable Detailed Description: Young men who have sex with men (YMSM) have unique needs for targeted and tailored HIV prevention messages. HIV infection

2006 Clinical Trials

15559. Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00294372 Recruitment Status : Terminated First Posted : February 22, 2006 Last

2006 Clinical Trials

15560. A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects

of selected doses of BMS-707035 administered orally to HIV-1 infected subjects for 10 days. Secondary Outcome Measures : Safety and tolerability with 10 days of dosing Effect on QTc intervals Effect on CD4+, CD8+, and CD8+CD38+ lymphocyte Pharmacokinetics of multiple doses of BMS-707035 in HIV-1 infected subjects Assess relationship of EC90 and exposures of BMS-707035 to the magnitude of change in viral loads Assess plasma protein binding and intracellular concentration in PBMC for BMS-707035 Eligibility (...) Volunteers: No Criteria Inclusion Criteria: HIV-1-infected subjects with CD4+ lymphocyte count ≥ 200 cells/mm3 and with plasma HIV-1 RNA ≥ 5000 copies/mL who have not been on antiretroviral (ARV) therapy for ≥ 8 weeks or who are naive to ARV, and who are otherwise medically stable as determined by medical history, physical examination, 12 lead electrocardiogram, and clinical laboratory evaluations will be eligible to participate in the study. In addition, subjects must have had no prior exposure

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>